Posted by admin on May 11th, 2022

DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) had its price target lowered by stock analysts at Barrington Research from $53.00 to $51.00 in a note issued to investors on Wednesday, The Fly reports. Barrington Research’s price objective would indicate a potential upside of 33.51% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Robert W. Baird cut DENTSPLY SIRONA from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $67.00 to $48.00 in a research report on Tuesday, April 19th. William Blair cut DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 19th. TheStreet cut DENTSPLY SIRONA from a “b-” rating to a “c+” rating in a research report on Friday, March 18th. Bank of America cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $66.00 to $49.00 in a research report on Tuesday, April 19th. Finally, The Goldman Sachs Group cut their price objective on DENTSPLY SIRONA from $59.00 to $47.00 and set a “neutral” rating for the company in a research report on Thursday, April 21st. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $52.89.

Shares of NASDAQ:XRAY traded up $1.82 on Wednesday, reaching $38.20. The company had a trading volume of 35,207 shares, compared to its average volume of 2,257,467. DENTSPLY SIRONA has a twelve month low of $35.00 and a twelve month high of $69.07. The stock has a 50-day moving average price of $46.56 and a 200 day moving average price of $51.57. The stock has a market capitalization of $8.23 billion, a P/E ratio of 19.90, a P/E/G ratio of 2.49 and a beta of 0.94. The company has a quick ratio of 1.12, a current ratio of 1.55 and a debt-to-equity ratio of 0.38.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.04). DENTSPLY SIRONA had a return on equity of 12.51% and a net margin of 9.90%. The business had revenue of $9.67 billion for the quarter, compared to analyst estimates of $982.05 million. During the same period in the prior year, the firm posted $0.72 EPS. DENTSPLY SIRONA’s revenue for the quarter was up 841.1% on a year-over-year basis. On average, sell-side analysts predict that DENTSPLY SIRONA will post 2.6 earnings per share for the current fiscal year.

In related news, Director Eric Brandt sold 6,900 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total transaction of $273,999.00. Following the transaction, the director now directly owns 35,155 shares in the company, valued at $1,396,005.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.69% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of DENTSPLY SIRONA by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 4,061,180 shares of the medical instruments supplier’s stock valued at $235,146,000 after purchasing an additional 109,108 shares during the period. Invesco Ltd. grew its stake in shares of DENTSPLY SIRONA by 12.9% in the 3rd quarter. Invesco Ltd. now owns 3,969,998 shares of the medical instruments supplier’s stock valued at $230,459,000 after purchasing an additional 454,358 shares during the period. Gabelli Funds LLC grew its stake in shares of DENTSPLY SIRONA by 118.8% in the 3rd quarter. Gabelli Funds LLC now owns 151,000 shares of the medical instruments supplier’s stock valued at $8,766,000 after purchasing an additional 82,000 shares during the period. Ensign Peak Advisors Inc grew its position in DENTSPLY SIRONA by 27.8% during the 3rd quarter. Ensign Peak Advisors Inc now owns 45,684 shares of the medical instruments supplier’s stock worth $2,652,000 after acquiring an additional 9,934 shares during the last quarter. Finally, Westpac Banking Corp grew its position in DENTSPLY SIRONA by 4.5% during the 4th quarter. Westpac Banking Corp now owns 23,388 shares of the medical instruments supplier’s stock worth $1,305,000 after acquiring an additional 999 shares during the last quarter. Institutional investors own 94.79% of the company’s stock.

About DENTSPLY SIRONA (Get Rating)

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

TransDigm Group (NYSE:TDG) PT Lowered to $620.00 at Susquehanna Bancshares

Ichor (NASDAQ:ICHR) Issues Q2 Earnings Guidance